ASKA Pharmaceutical Holdings Co Ltd
TSE:4886

Watchlist Manager
ASKA Pharmaceutical Holdings Co Ltd Logo
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Watchlist
Price: 2 304 JPY -3.23%
Market Cap: 65.4B JPY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
ASKA Pharmaceutical Holdings Co Ltd

Wall Street analysts forecast ASKA Pharmaceutical Holdings Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASKA Pharmaceutical Holdings Co Ltd is 2 652 JPY with a low forecast of 2 626 JPY and a high forecast of 2 730 JPY.

Lowest Forecast
Wall Street Target
2 626 JPY
14% Upside
Average Forecast
Wall Street Target
2 652 JPY
15% Upside
Highest Forecast
Wall Street Target
2 730 JPY
18% Upside
Lowest
Price Target
2 626 JPY
14% Upside
Average
Price Target
2 652 JPY
15% Upside
Highest
Price Target
2 730 JPY
18% Upside
ASKA Pharmaceutical Holdings Co Ltd Competitors:
Price Targets
ITCI
Intra-Cellular Therapies Inc
1% Upside
M
MANKIND
Mankind Pharma Ltd
11% Upside
Z
603456
Zhejiang Jiuzhou Pharmaceutical Co Ltd
32% Upside
4578
Otsuka Holdings Co Ltd
37% Upside
ITCI
Intra-Cellular Therapies Inc
1% Upside
M
MANKIND
Mankind Pharma Ltd
11% Upside
Z
603456
Zhejiang Jiuzhou Pharmaceutical Co Ltd
32% Upside
4578
Otsuka Holdings Co Ltd
37% Upside
4887
Sawai Group Holdings Co Ltd
24% Upside
Z
600267
Zhejiang Hisun Pharmaceutical Co Ltd
25% Downside

Revenue
Forecast

Revenue Estimate
ASKA Pharmaceutical Holdings Co Ltd

For the last 7 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 3%.

4%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ASKA Pharmaceutical Holdings Co Ltd

Operating Income forecast
is not available for
ASKA Pharmaceutical Holdings Co Ltd

Net Income
Forecast

Net Income Estimate
ASKA Pharmaceutical Holdings Co Ltd

For the last 7 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's net income is 14%. The projected CAGR for the next 3 years is -7%.

14%
Past Growth
-7%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASKA Pharmaceutical Holdings Co Ltd's stock price target?
Price Target
2 652 JPY

According to Wall Street analysts, the average 1-year price target for ASKA Pharmaceutical Holdings Co Ltd is 2 652 JPY with a low forecast of 2 626 JPY and a high forecast of 2 730 JPY.

What is ASKA Pharmaceutical Holdings Co Ltd's Revenue forecast?
Projected CAGR
3%

For the last 7 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 3%.

What is ASKA Pharmaceutical Holdings Co Ltd's Net Income forecast?
Projected CAGR
-7%

For the last 7 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's net income is 14%. The projected CAGR for the next 3 years is -7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.